Stuttgart - Delayed Quote EUR
Ardelyx Inc (41X.SG)
As of 7:26 PM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
251,849.00
124,456.00
52,158.00
10,097.00
7,571.00
Cost of Revenue
37,369.00
17,795.00
4,117.00
1,000.00
145.00
Gross Profit
214,480.00
106,661.00
48,041.00
9,097.00
7,426.00
Operating Expense
278,541.00
169,937.00
111,800.00
163,443.00
98,206.00
Operating Income
-64,061.00
-63,276.00
-63,759.00
-154,346.00
-90,780.00
Net Non Operating Interest Income Expense
-17,046.00
-8,874.00
-5,073.00
-4,502.00
-5,099.00
Other Income Expense
9,088.00
6,630.00
1,633.00
687.00
1,568.00
Pretax Income
-72,019.00
-65,520.00
-67,199.00
-158,161.00
-94,311.00
Tax Provision
564.00
547.00
8.00
4.00
2.00
Net Income Common Stockholders
-72,583.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
Diluted NI Available to Com Stockholders
-72,583.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
Basic EPS
-0.27
-0.30
-0.42
-1.52
-1.05
Diluted EPS
-0.27
-0.30
-0.42
-1.52
-1.05
Basic Average Shares
230,736.03
219,331.25
158,690.08
104,205.65
89,582.14
Diluted Average Shares
230,736.03
219,331.25
158,690.08
104,205.65
89,582.14
Total Operating Income as Reported
-64,061.00
-63,276.00
-63,759.00
-154,346.00
-90,780.00
Total Expenses
315,910.00
187,732.00
115,917.00
164,443.00
98,351.00
Net Income from Continuing & Discontinued Operation
-72,583.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
Normalized Income
-72,583.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
Interest Expense
17,046.00
8,874.00
5,073.00
4,502.00
5,099.00
Net Interest Income
-17,046.00
-8,874.00
-5,073.00
-4,502.00
-5,099.00
EBIT
-54,973.00
-56,646.00
-62,126.00
-153,659.00
-89,212.00
EBITDA
-53,063.00
-55,354.00
-60,982.00
-150,852.00
-86,671.00
Reconciled Cost of Revenue
37,369.00
17,795.00
4,117.00
1,000.00
145.00
Reconciled Depreciation
1,910.00
1,292.00
1,144.00
2,807.00
2,541.00
Net Income from Continuing Operation Net Minority Interest
-72,583.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
Normalized EBITDA
-53,063.00
-55,354.00
-60,982.00
-150,852.00
-86,671.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 10/13/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LT4.F Liquidia Corporation
9.75
+2.74%
1JK.F Apellis Pharmaceuticals, Inc.
26.08
-3.39%
1VT.F Viking Therapeutics, Inc.
62.98
+4.69%
1VT.BE Viking Therapeutics Inc
62.22
+1.73%
IBIO iBio, Inc.
2.5300
-1.56%
BPMC Blueprint Medicines Corporation
102.35
+2.73%
BMEA Biomea Fusion, Inc.
8.22
-7.43%
CCCC C4 Therapeutics, Inc.
6.07
+1.59%
BAVA.CO Bavarian Nordic A/S
204.00
+2.00%
CPRX Catalyst Pharmaceuticals, Inc.
23.47
+3.35%